A. Armour

发表

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

T. Mok, Yi-long Wu, S. Thongprasert, 2009, The New England journal of medicine.

Apoptosis in cervical squamous carcinoma: predictive value for survival following radiotherapy

A. Armour, J. Mao, R. Symonds, 2000, Journal of clinical pathology.

Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small cell lung cancer (NSCLC): Meta-analysis from four clinical trials.

Edward S. Kim, N. Saijo, A. Armour, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study.

H. Kato, M. Tsuboi, S. Kudoh, 2008, American journal of respiratory and critical care medicine.

Reply to D. Tassinari et al

Edward J. Kim, Y. Ichinose, A. Armour, 2009 .

Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.

Edward S. Kim, M. Socinski, C. Watkins, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

B3-02: Randomized, double-blind, multicenter, parallel-group, Phase II study of gefitinib (IRESSA) plus best supportive care (BSC) versus placebo plus BSC in chemotherapy-naïve patients with advanced non-small-cell lung cancer and poor performance status (INSTEP)

E. Duffield, A. Armour, D. Ferry, 2007 .

Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS).

T. Mok, Yi-long Wu, S. Thongprasert, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TREATMENT PERIODS AND SUBJECTS IN THE COHORT AND NUMBER OF CASES AND CONTROLS IN THE NESTED CASE-CONTROL

H. Kato, M. Tsuboi, S. Kudoh, 2008 .

Ectopic cervical hamartomatous thymoma showing extensive myoid differentiation

A. Armour, J. Williamson, 1993, The Journal of Laryngology & Otology.

Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes

M. Piccart, Z. Aziz, D. Fraser, 2017, The Pharmacogenomics Journal.

Molecular and clinical subgroup analyses from a phase III trial comparing gefitinib with docetaxel in previously treated non-small cell lung cancer (INTEREST)

Edward S. Kim, M. Socinski, T. Mok, 2008 .

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.

E. Perez, R. Gelber, J. Baselga, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HLA-DRB1*07:01 biomarker characterization of hepatotoxicity during lapatinib combination therapies in ALTTO.

Z. Aziz, D. Fraser, L. Warren, 2015 .

Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

K. Rahbar, M. Morris, B. Krause, 2021, The New England journal of medicine.

Modification of meta-iodobenzylguanidine uptake in neuroblastoma cells by elevated temperature.

A. Armour, M. Gaze, T. Wheldon, 1994, British Journal of Cancer.

The effect of cisplatin pretreatment on the accumulation of MIBG by neuroblastoma cells in vitro.

A. Armour, M. Gaze, T. Wheldon, 1997, British Journal of Cancer.

Whole exome sequencing of pre-treatment biopsies from the neoALTTO trial to identify DNA aberrations associated with response to HER2-targeted therapies

C. Sotiriou, L. Pusztai, J. Baselga, 2015 .

Erythema anulare centrifugum associated with disseminated prostatic carcinoma.

A. Armour, A. Burden, V. Gudi, 2002, Acta dermato-venereologica.

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial

C. Sotiriou, S. Loi, L. Pusztai, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

Masahiro Fukuoka, Haiyi Jiang, Kazuhiko Nakagawa, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

Edward S. Kim, Scott M Lippman, Jean-Yves Douillard, 2008, The Lancet.

Microcystic endometrioid carcinoma of the Fallopian tube simulating an adnexal tumour of probable Wolffian origin

A. Armour, J. Williamson, 1993, Histopathology.

Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study.

F. Cappuzzo, F. Hirsch, E. Duffield, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BiomarkerAnalysesandFinalOverallSurvivalResultsFroma PhaseIII,Randomized,Open-Label,First-LineStudyofGefitinib VersusCarboplatin/PaclitaxelinClinicallySelectedPatientsWith AdvancedNon-Small-CellLungCancerinAsia(IPASS)

T. Mok, Yi-long Wu, S. Thongprasert, 2011 .

The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer

A. Armour, C. Watkins, 2010, European Respiratory Review.

Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer

H. Iwata, A. Armour, Kenichi Inoue, 2015, International Journal of Clinical Oncology.

PSMA heterogeneity analysis in patients with metastatic castrate-resistant prostate cancer (mCRPC): Imaging versus CTCs.

M. Morris, A. Tolcher, A. Armour, 2018 .

Microinvasive lobular carcinoma of the breast

A. Armour, I. Ellis, A. Howat, 2000, Histopathology.

Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status.

F. Hirsch, E. Duffield, A. Armour, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

C. Sotiriou, S. Loi, L. Pusztai, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Jie Yang, Yi-long Wu, S. Thongprasert, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation.

A. Armour, M. Gaze, R. Mairs, 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].

F. Hirsch, A. Armour, M. Varella‐Garcia, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gefitinib in advanced non‐small cell lung cancer: Clinical experience in patients of Asian origin

A. Armour, 2007 .

Phase 1 dose-escalation study of the folic acid-tubulysin small-molecule drug conjugate (SMDC) folate-tubulysin EC1456: Study update

A. Armour, M. Edelman, J. Sachdev, 2016 .

A Phase III randomized parallel-group study of gefitinib (IRESSA) versus methotrexate (IMEX) in patients with recurrent squamous cell carcinoma of the head and neck

A. Armour, E. Vokes, P. Vodvářka, 2007 .

B3-04: Gefitinib (IRESSA) versus vinorelbine in chemonaïve elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized Phase II study

F. Hirsch, E. Duffield, A. Armour, 2007 .

Phase 1 study of the PSMA-targeted tubulysin small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC).

M. Morris, A. Tolcher, A. Armour, 2015 .

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

C. Sotiriou, S. Loi, L. Pusztai, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

A case of squamous cell carcinoma associated with plasmacytoma.

A. Armour, G. Ross, M. Berry, 2004, British journal of plastic surgery.